| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e7c880bd420e150f0c4a52776232c2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0723ac2f397223ca017c2963d0a599e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_042dabf28a12c5008c5c30e753ab31e1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
1989-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b5ccd661e032ffca89a5f00ff1e2550
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e1a3731b285f3f335656b469103891c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6a810d67fdac2aedfd0c7f5e2b3e3d9 |
| publicationDate |
2002-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-1341391-C |
| titleOfInvention |
Protective peptides derived from human immunodeficiency virus-1 gp160 |
| abstract |
A peptide comprising an amino acid sequence of up to 50 amino acids that corresponds to at least a port ion of a protective epitope of HIV and includes an amino acid sequence chosen from the group consisting of:-(a) gly-glu-ile-lys-asn-cys-ser-phe-asn-ile-ser-thr-ser-ile-arg-gly-lys-val-gln-lys-glu-tyr-ala; (b) asn-gly-asn-ala-glu-glu-val-val-ile-arg-ser-ala-asn-phe-thr-asp-asn -ala-lys-thr-ile-ile-val; (c) cys-asn-ile-ser-arg-ala-Lys-trp-asn-asn-thr-leu-lys-gln-ile-asp-ser-lys-leu-arg-glu-gln-phe; (d) gly-ser-asp-thr-ile-thr-leu-pro-cys-arg-ile-lys-gln-ile-ile-asn-met-trp-gln-glu-val-gly-lys ; and (e) val-gln-gln-gln-asn-asn-leu-leu-arg-ala-thr-glu-ala-gln-his-leu-leu-gln-leu-thr-val-thp-gly-ile-lys-gln-leu-gln. The disclosed peptides are immunologically cross-reactive with human immunodeficiency virus 41,000 dalton glycoprotein gp41. These novel peptides are useful in methods of interfering with the effects of HIV-1 upon host cells having cell surface polypeptides capable of binding HIV-1. |
| priorityDate |
1988-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |